Zejing Pharmaceutical announced that the company and AbbVie reached a strategic cooperation and licensing option agreement for the global development and commercialization of ZG006. AbbVie has obtained exclusive development and commercialization rights for ZG006 outside of Greater China, and Ze Jing reserves the relevant rights in Greater China. Ze Jing will receive a down payment of 100 million US dollars and up to 60 million US dollars in payment related to recent milestones and license options; if AbbVie exercises the right to choose, Zejing can receive a milestone payment of up to US$1,075 million and charge tiered royalties for net sales outside of Greater China. The transaction does not constitute a related or major asset restructuring and has been reviewed by the board of directors. ZG006's overseas approval, commercialization, and subsequent payment amounts are all at risk.

Zejing Pharmaceutical announced that the company and AbbVie reached a strategic cooperation and licensing option agreement for the global development and commercialization of ZG006. AbbVie has obtained exclusive development and commercialization rights for ZG006 outside of Greater China, and Ze Jing reserves the relevant rights in Greater China. Ze Jing will receive a down payment of 100 million US dollars and up to 60 million US dollars in payment related to recent milestones and license options; if AbbVie exercises the right to choose, Zejing can receive a milestone payment of up to US$1,075 million and charge tiered royalties for net sales outside of Greater China. The transaction does not constitute a related or major asset restructuring and has been reviewed by the board of directors. ZG006's overseas approval, commercialization, and subsequent payment amounts are all at risk.